BioMan4R2 aims to improve manufacturing processes and strengthen the competitiveness and sustainability of the European healthcare ecosystem. This is to be achieved through long-term collaboration between SMEs, investment funds, research, clinical and scientific organizations and science and technology parks.
To this end, the BioMan4R2 project has offered financial support and networking under the European SMP COSME program for small and medium-sized enterprises in the biomanufacturing and medical technology (BMT) sectors that want to increase their resilience, sustainability and competitiveness.
BioMan4R2 in detail
The first phase of the BioMan4R2 project focused on preparing and building Eurocluster excellence to meet the critical needs of the BMT sector. The project has three main tasks:
- Identify resilience needs of the BMT sector.
- Make stakeholders and service providers visible.
- Establish an SME support program.
The BioMan4R2 Eurocluster consists of a comprehensive transnational network covering the entire value chain of the BMT sector. SMEs can contact the project partners to get in touch with potential cooperation partners.
Find out more about BioMan4R2's goals and achievements
Project partners
- Turku Science Park Oy Ab (FI, Leadpartner)
- Bioregio STERN (DE)
- LifetecZONe (NL)
- Upper Silesian Accelerator for Commercial Enterprises Ltd (PL)
- Medicen Paris Region (FR)
- Council of European Bioregions (BE)
- Biocat (CAT)
BioMan4R2 SME Support Program & Call Results
In this document, you will find the BioMan4R2 support program and the results of the call.
Further information
Visit the BioMan4R2 project on the European Cluster Collaboration Platform (ECCP) to stay updated on the latest activities.
Stakeholder mapping for the SME funding program - BioMan4R2 Eurocluster at a glance
The aim of the second phase is to increase the resilience, sustainability and competitiveness of SMEs in the biomanufacturing and medical technology sectors through the support program. The objectives of this second phase are:
- Establish new cooperation models between European biomanufacturing cluster organizations and other key stakeholders in the pharmaceutical/biomedical and medical device sectors.
- Facilitate the signing of cooperation agreements between European institutions and institutions in third countries.
- To facilitate the implementation and adoption of innovation in business processes and contribute to green and digital transformation.
- To improve the cluster management capabilities of the consortium to provide better services and attract more talents to BMT.
- Improve and transform BMT products in a way that reduces dependency on current value chains and introduce new innovative products.
SMEs benefit from the opportunities offered by BioMan4R2 - financial support to promote resilience, sustainability and competitiveness
With the financial support of a maximum of €60,000, SMEs can tackle a wide range of challenges that are usually not supported by standard funding programs or investors. These can include training plans, support for travel to explore markets outside the EU, MDR implementation, business continuity and resilience plans.
The winners were announced on July 18, 2023.
BioMan4R2-winners are:
Innovation financial support (IFS)
| IFS Gewinner | Land | Projekt Titel | Kategorie | Co-Partner (Land) |
|---|---|---|---|---|
| *Robeauté | FR | Microrobots for neurosurgery - revolutionising access to complex areas of the central nervous system | Neurology | FEMTIKA (LT) AMAROB (FR) |
| *Plantibodies | FR | Plant-Based Oral Immunotherapy for Gastrointestinal Diseases: A Resilient Bioproduction Approach | Gastroenterology | Prodigest (BE) CDMO (BE) |
| InSpek SAS | FR | On-chip Raman spectroscopy sensors to monitor in-line and in real time the bioproduction | Bioproduction | URD ABI AgroParisTech (FR) |
| Antleron NV | BE | 3D-printing and beta-testing of customised 3D fixed bed (3D-FB) cell culture disposables | Manufacturing process | Leuven Viral Vector Core (LVVC) (BE) |
| *Fibrothelium GmbH | DE | Biosynthetic protein production in plants for bioabsorbable implants | Bioproduction | Aachen-Maastricht Institute for Biobased Materials (NL) |
| ATTOM | FR | New modular device to support other companies to create and test complex in vitro models for preclinical research purposes | Validation process | Healshape (FR) ICO (FR) UCBL labs (FR) |
| MindAhead UG | DE | Validation of digital therapy tool for improving brain health | Neurology | Medical Innovations Incubator GmbH (DE) |
| *ALTA sp. z o.o. | PL | Validation of a new psychological memory test | Neurology | Prometriks Ltd (BG) |
| *MIRA Vision Microscopy GmbH | DE | Scaling up AI-assisted image analysis for microscopy | Imaging | Jaydevs LLC (LT) |
| Time is Brain SL | ES | Validation real-time brain monitoring tools of stroke patients | Neurology | University Hospital La Princesa (ES) University Hospital Sant Pau (ES) University Hospital Arnau de Vilanova (ES) |
| MAGIC GENOMIX | FR | Revolutionizing cancer treatment by developing a theragnostic solution, relevant in multiple cancer types | Oncology | ValoTec (FR) |
| *PolyAn GmbH | DE | Filling the gap: Automated production line for glass slides with reactive surface functionalization | Imaging | Eccom OÜ (EE) Herbert Stamm KG (DE) |
| *IntegraSkin GmbH | DE | Overcoming regulatory, economic, and market entry barriers for diagnostic device providing effective treatment plans for chronic skin conditions | Dermatology | Medical Innovations Incubator GmbH (DE) ITSAN NGO (USA) Charité IFA (DE) Bestseller Verlag GmbH (DE) |
| *Basic Pharma | NL | Reducing pharmaceutical development time and costs and increase the change of success by setting up a European joint supply chain for the GMP production of biologicals | Manufacturing process | ARTES Biotechnology GmbH (DE) |
| *Care4living Oy | FI | Validation of cost-effective fermentation and purification process for a cytotoxic small molecule drug | Manufacturing process | University of Turku (FI) NIHM BV (NL) |
| *EVOMEDIS GmbH | AT | EVOCornea – validation of a cell-based therapy for the treatment of corneal defects | Ophthalmology | University Clinic Düsseldorf (DE) |
*Cross-border cooperation
Business transformation financial support (BTFS)
| BTFS Gewinner | Land | Projekt Titel | Kategorie | Co-Partner (Land) |
|---|---|---|---|---|
| SITEC pharmabio | ES | Business Continuity Plan to aligned with the regulatory requirements of Pharma and Nutra sectors | Business legal /financial analysis | GENESIS Biomed (ES) |
| *Zeisberg GmbH | DE | Market Entry beyond Europe of a new video oculography system | Go International | AHK Kanada (CA) Emergo by UL (USA) DQS DE |
| *Egerton sp. z o.o. | PL | Transitioning to MDR for class I medical devices, including gap analysis, clinical evaluation, and EMC testing | Train your worker- Go Greener/Digital | novineon CRO (DE) ELZAB Laboratory (PL) |
| Manitty | FR | Developing a headband in line with European regulations in terms of RGPD, CE marking and MDR | Business legal /financial analysis | SQI (FR) |
| JAFRAL d.o.o. | SI | Creating a specialized digital module for managing service providers to comply with GMP standards | Train your worker- Go Greener/Digital | Miran Janežič s.p. (SI) |
| *Breaz Medical SL | ES | Creating clinical evaluation plan under the provisions of the MDR for a lung disease diagnostic device | Business legal /financial analysis | novineon CRO GmbH (DE) |
| Earlab GmbH | DE | Implementation of the QMS and the commencement of compliant development of a medical device for hearing assessment | Business legal /financial analysis | Medical Innovations Incubator GmbH (DE) |
| Egerton sp. z o.o. | PL | Legal, market, and resilience analysis to outline the regulatory landscape, market dynamics, and potential obstacles for a system for digitizing nursing rounds | Business legal /financial analysis | Scheelite Sp. z o.o. (PL) |
| *Gate2Brain S.L. | ES | Strategic roadmap of Market Access to achieve the inclusion of a drug candidate to treat pediatric cancer patients in different Early Access Programs in the EU | Business legal /financial analysis | AliraHealth SAS (FR) |
| ONIRIA THERAPEUTICS, S.L. | ES | Market Access analysis to gain a comprehensive understanding of the four key European markets and the UK for melanoma treatment. | Go International | Alira Health SLU (ES) |
*Cross-border cooperation
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.